Journal
PHARMACOLOGY & THERAPEUTICS
Volume 228, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2021.107920
Keywords
Diabetes; Cardiomyopathy; Cardiac dysfunction; Hyperglycemia; Outcome
Categories
Funding
- Forschungskommission of theMedical Faculty of the Heinrich Heine University [46-2016, 29-2019, 16-2014]
- German Research Foundation [LE 940/7-1, PO 2247/2-1, SFB1116]
Ask authors/readers for more resources
Diabetic cardiomyopathy is a common cardiac complication in diabetic patients, characterized by structural and functional changes in the myocardium, leading to a high incidence of heart failure. Current therapeutic options mainly focus on improving the abnormal states of inflammation, apoptosis, reactive oxygen species, and calcium signaling at the cardiomyocyte level.
Diabetes mellitus (DM) is associated with a specific cardiac phenotype characterized by structural and functional alterations. This so-called diabetic cardiomyopathy (DM CM) is clinically relevant as patients with DM show high incidence of heart failure. Mechanistically, several parameters interact on the cardiomyocyte level leading to increased inflammation, apoptosis, reactive oxygen species and altered calcium signaling. This in turn provokes functional myocardial changes that might inter alia play into the worsened clinical outcome in DM patients. Therefore, efficient therapeutic options are urgently needed. This review focuses on mechanistic effects of currently recommended antidiabetic treatment and heart failure therapy for DM CM. (c) 2021 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available